Evidence map›Paper›PMID 27852671›Full record

ArticleJournal of clinical microbiology2017

Highly Multiplexed Proteomic Analysis of Quantiferon Supernatants To Identify Biomarkers of Latent Tuberculosis Infection.

Mary Ann De Groote, Michael Higgins, Thomas Hraha, Kirsten Wall, Michael L Wilson, David G Sterling, Nebojsa Janjic, Randall Reves, Urs A Ochsner, Robert Belknap

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in Journal of clinical microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Mary Ann De GrooteSomaLogic, Inc., Boulder, Colorado, USA.
Michael HigginsDepartment of Pathology and Laboratory Services, Denver Health, Denver, Colorado, USA.
Thomas HrahaSomaLogic, Inc., Boulder, Colorado, USA.
Kirsten WallSomaLogic, Inc., Boulder, Colorado, USA.
Michael L WilsonDepartment of Pathology and Laboratory Services, Denver Health, Denver, Colorado, USA.
David G SterlingSomaLogic, Inc., Boulder, Colorado, USA.
Nebojsa JanjicSomaLogic, Inc., Boulder, Colorado, USA.
Randall RevesDenver Health and Hospital Authority and Denver Public Health, Denver, Colorado, USA.
Urs A OchsnerSomaLogic, Inc., Boulder, Colorado, USA uochsner@somalogic.com Robert.belknap@dhha.org.
Robert BelknapDenver Health and Hospital Authority and Denver Public Health, Denver, Colorado, USA uochsner@somalogic.com Robert.belknap@dhha.org.
SomaLogic (United States) · USDenver Health Medical Center · USColorado State University · USUniversity of Colorado Denver · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tests for diagnosing latent tuberculosis infection (LTBI) are limited by a poor predictive value for identifying people at the highest risk for progressing to active tuberculosis (TB) and have various sensitivities and specificities in different populations. Identifying a more robust signature for LTBI is important for TB prevention and elimination. A pilot study was conducted with samples from immigrants to the United States that were screened for LTBI by the three commercially approved tests, namely, the tuberculin skin test (TST), the Quantiferon-TB Gold in-tube (QFT-GIT), and the T-SPOT.TB (T-SPOT). QFT-GIT supernatants from 13 people with concordant positive results and 26 people with concordant negative results were analyzed via the highly multiplexed SOMAscan proteomic assay. The proteins in the stimulated supernatants that distinguished LTBI from controls included interleukin-2 (IL-2), monocyte chemotactic protein 2 (MCP-2), interferon gamma inducible protein-10 (IP-10), interferon gamma (IFN-γ), tumor necrosis factor superfamily member 14 (TNFSF14, also known as LIGHT), monokine induced by gamma interferon (MIG), and granzyme B (P <0.00001). In addition, antigen stimulation increased the expression of heparin-binding EGF-like growth factor (HB-EGF) and activin AB in LTBI samples. In nil tubes, LIGHT was the most significant marker (P <0.0001) and was elevated in LTBI subjects. Other prominent markers in nonstimulated QFT-GIT supernatants were the complement-3 components C3b, iC3b, and C3d, which were upregulated in LTBI and markedly decreased upon stimulation. We found known and novel proteins that warrant further studies for developing improved tests for LTBI, for predicting progression to active disease, and for discriminating LTBI from active TB.

Indexed as

AdolescentAdultBiomarkersEmigrants and ImmigrantsEnzyme-Linked Immunospot AssayFemaleHumansImmunologic FactorsInterferon-gamma Release TestsLatent TuberculosisMaleMiddle AgedProteomeProteomicsTuberculin TestUnited StatesBiomarkersImmunologic FactorsProteomebiomarkersdiagnosisimmunitylatent infectionproteomicstuberculosis

Identifiers

PMID27852671
PMCPMC5277508
OpenAlexW2552402531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.